Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Keratosis, Actinic 10Condylomata Acuminata 3Virus Diseases 1Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Non-Muscle Invasive Bladder Neoplasms 1Non-Melanoma Skin Cancers 1Neoplasms 1Lymphoma, Follicular 1Keratosis, Seborrheic 1Exanthema 1Carcinoma, Non-Small-Cell Lung 1Acne Vulgaris 1

Interventions

Rituximab 90Cyclophosphamide 30Lenalidomide 28Bendamustine Hydrochloride 24Prednisone 20Vincristine 19obinutuzumab 17Doxorubicin 16fludarabine 14ibrutinib 13tazemetostat 9idelalisib 9Deoxycholic Acid 9parsaclisib 8Prednisolone 8zanubrutinib 7venetoclax 7tofacitinib 7tisagenlecleucel 5pembrolizumab 5ofatumumab 5ibritumomab tiuxetan 5duvelisib 5Gemcitabine 5Bortezomib 5durvalumab 4aflibercept 4R-CHOP protocol 4Methylprednisolone 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Follicular × Gels × Clear all
NCT02796066 2017-04-26

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

Thesan Pharmaceuticals, Inc.

Phase 2 Withdrawn
Lymphoid

Acne Vulgaris, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡